WILLIAM CRAIG: Open Payments
NPI 1396265427 · DERIDDER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 42 payments from 10 companies in 2025. Trend: 2023 $330 · 2024 $662 · 2025 $979
Food & beverage: $862Education: $117
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 14 | $319 |
| Teva Pharmaceuticals USA, Inc. | 8 | $249 |
| Alkermes, Inc. | 4 | $86 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| ABBVIE INC. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
Products named: Qelbree, ARISTADA, UZEDY, SPRAVATO, AUSTEDO XR, COBENFY, CAPLYTA, VRAYLAR.
Industry payments across LA — which companies pay providers there.
